Microparticles as a strategy for low-molecular-weight heparin delivery
β Scribed by Samantha S. M. Oliveira; Fabiana S. Oliveira; Cristiane M. Gaitani; Juliana M. Marchetti
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 312 KB
- Volume
- 100
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
β¦ Synopsis
The aims of this work were preparation and physical-chemical characterization of a microparticulate release system for delivery of enoxaparin sodium (ENX), a low-molecular-weight heparin, as a potential vehicle for optimization of deep venous thrombosis therapy. Microparticles (MPs) containing ENX were prepared from polylactide-co-glycolic acid [PLGA; (50:50)] by a double emulsification/solvent evaporation method. The preparation parameters, such as proportion ENX/PLGA, surfactant concentration, type, time, and speed of stirring, were evaluated. The encapsulation efficiency and yield process were determined and optimized, and the in vitro release profile was analysed at 35 days. The MPs showed a spherical shape with smooth and regular surfaces. The size distribution showed a unimodal profile with an average size of 2.0 Β± 0.9 ΞΌ m. The low encapsulation efficiency (<30%), characteristic of hydrophilic macromolecules was improved, reaching 50.2% with a procedure yield of 71.3%. The in vitro profile of ENX release from the MPs was evaluated and showed pseudo-zero-order kinetics. This indicated that diffusion was the main drug release mechanism.
π SIMILAR VOLUMES
Abstract In a prospective, double-blind controlled study we have compared the prophylactic efficacy against deep vein thrombosis of low-dose heparin + dihydroergotamine (A), low molecular weight heparin + dihydro-ergotamine (B) and placebo (C). A total of three hundred and fifty-six patients undergo
## Abstract Although heparin can regulate angiogenesis, tumor growth and metastasis, its clinical application, as well as that of lowβmolecular heparin (LMWH), for treating cancer are limited because of heparin's anticoagulant activity and risk of hemorrhages. LMWHβtaurocholate conjugates (LHT7), w